<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3726622</article-id><article-id pub-id-type="pmid">23922981</article-id><article-id pub-id-type="publisher-id">PONE-D-13-07849</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0070324</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Developmental Biology</subject><subj-group><subject>Morphogenesis</subject><subj-group><subject>Cell Migration</subject></subj-group></subj-group></subj-group><subj-group><subject>Genetics</subject><subj-group><subject>Gene Function</subject></subj-group></subj-group><subj-group><subject>Molecular Cell Biology</subject><subj-group><subject>Signal Transduction</subject><subj-group><subject>Signaling Cascades</subject><subj-group><subject>WNT Signaling Cascade</subject></subj-group></subj-group></subj-group><subj-group><subject>Cell Adhesion</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Pathology</subject><subj-group><subject>General Pathology</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group></subj-group><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Gastrointestinal Tumors</subject><subj-group><subject>Hepatocellular Carcinoma</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Overexpression of CTHRC1 in Hepatocellular Carcinoma Promotes Tumor Invasion and Predicts Poor Prognosis </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">CTHRC1 in Hepatocellular Carcinoma</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yu-Ling</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Ting-Huang</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hsu</surname><given-names>Hey-Chi</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Ray-Hwang</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jeng</surname><given-names>Yung-Ming</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Graduate Institute of Pathology, National Taiwan University, Taipei, Taiwan</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Wong</surname><given-names>Chun-Ming</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of Hong Kong, Hong Kong</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>mrna0912@yahoo.com.tw</email></corresp><fn fn-type="COI-statement"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con"><p><text><SENT sid="2" pm="."><plain>Conceived and designed the experiments: YMJ. </plain></SENT>
<SENT sid="3" pm="."><plain>Performed the experiments: YLC THW. </plain></SENT>
<SENT sid="4" pm="."><plain>Analyzed the data: YMJ HCH RHY. </plain></SENT>
<SENT sid="5" pm="."><plain>Contributed reagents/materials/analysis tools: HCH. </plain></SENT>
<SENT sid="6" pm="."><plain>Wrote the paper: YMJ YLC. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>29</day><month>7</month><year>2013</year></pub-date><volume>8</volume><issue>7</issue><elocation-id>e70324</elocation-id><history><date date-type="received"><day>20</day><month>2</month><year>2013</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 Chen et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Chen et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="7" pm="."><plain>Collagen triple helix repeat containing-1 (CTHRC1) is a secreted glycoprotein that activates the planar cell polarity pathway of Wnt signaling. </plain></SENT>
<SENT sid="8" pm="."><plain>Using microarray analysis, we found that the CTHRC1 gene is overexpressed in hepatocellular carcinoma (HCC). </plain></SENT>
<SENT sid="9" pm="."><plain>The level of CTHRC1 mRNA was measured in 201 surgically resected HCCs using real time reverse transcription-polymerase chain reaction. </plain></SENT>
<SENT sid="10" pm="."><plain>Overexpression of CTHRC1 in HCC was associated with large tumor size and advanced tumor stage. </plain></SENT>
<SENT sid="11" pm="."><plain>Furthermore, expression of CTHRC1 as was identified as an independent prognostic factors in the multivariate analysis. </plain></SENT>
<SENT sid="12" pm="."><plain>Suppression of CTHRC1 expression inhibited tumor migration and invasion whereas overexpression of CTHRC1 promoted tumor invasion. </plain></SENT>
<SENT sid="13" pm="."><plain>Activation of RhoA, but not Rac1 or Cdc42, was found to play a crucial role in CTHRC1-induced cell migration. </plain></SENT>
<SENT sid="14" pm="."><plain>CTHRC1 promoted adhesion of cancer cells to extracellular matrix through induction of integrin β1 expression and activation of focal adhesion kinase. </plain></SENT>
<SENT sid="15" pm="."><plain>These results suggest CTHRC1 promotes tumor invasion and metastasis by enhancing the adhesion and migratory abilities of tumor cells. </plain></SENT>
<SENT sid="16" pm="."><plain>It is also a promising biomarker for predicting the prognosis of patients with HCC. </plain></SENT>
</text></SecTag></p></abstract><funding-group><funding-statement>This study was supported by a grant from National Science Council, Taiwan, Republic of China. (100-2320-B-002-011-MY3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="10"/></counts></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="17" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="18" pm="."><plain>Hepatocellular carcinoma (HCC) is one of the most common fatal malignancies in Taiwan and many other countries in Asia and Africa [1]. </plain></SENT>
<SENT sid="19" pm="."><plain>Its incidence is increasing in Western countries, mainly due to the prevalence of chronic hepatitis C infection [2]. </plain></SENT>
<SENT sid="20" pm="."><plain>The major risk factors are hepatitis B and hepatitis C infections, cirrhosis of any etiology, and aflatoxin exposure [3]. </plain></SENT>
<SENT sid="21" pm="."><plain>Molecular approaches have revealed the involvement of p53 and β-catenin mutations in hepatocarcinogenesis [4], [5]. </plain></SENT>
<SENT sid="22" pm="."><plain>The mutations account for approximately 50% of all HCC cases. </plain></SENT>
<SENT sid="23" pm="."><plain>Somatic mutations of other known oncogenes and tumor suppressor genes in HCC are rare. </plain></SENT>
<SENT sid="24" pm="."><plain>Hence, the molecular mechanisms of HCC, particularly in the early stage, remain largely unclear. </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>Collagen triple helix repeat containing-1 (CTHRC1) is a 25-kDa secreted glycoprotein containing an NH2-terminal peptide for extracellular secretion, a short collagen triple helix repeat of 36 amino acids, and a COOH-terminal globular domain [6]. </plain></SENT>
<SENT sid="26" pm="."><plain>It was initially found in a screen for differentially expressed genes in balloon-injured versus normal rat arteries [6]. </plain></SENT>
<SENT sid="27" pm="."><plain>Expression of Cthrc1 was induced abundantly in adventitial fibroblasts and neointimal smooth muscle cells of balloon-injured vessels [6]. </plain></SENT>
<SENT sid="28" pm="."><plain>Forced expression of Cthrc1 in rat fibroblasts promoted cell migration and inhibited collagen I synthesis in these cells, indicating Cthrc1 may contribute to tissue repair in vascular remodeling in response to injury by limiting collagen matrix deposition and promoting cell migration [6]. </plain></SENT>
<SENT sid="29" pm="."><plain>Likewise, Cthrc1 transgenic mice showed reduced neointimal lesion formation and adventitial collagen deposition in response to carotid artery ligation [7]. </plain></SENT>
<SENT sid="30" pm="."><plain>The molecular mechanisms of Cthrc1 are yet to be discovered. </plain></SENT>
<SENT sid="31" pm="."><plain>In smooth muscle of arteries, Cthrc1 inhibits the signaling of transforming growth factor-β [7]. </plain></SENT>
<SENT sid="32" pm="."><plain>Recently, Cthrc1 was found to selectively activate the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex [8]. </plain></SENT>
</text></p><p><text><SENT sid="33" pm="."><plain>The human homolog of CTHRC1 shares 92% sequence identity with the rat protein. </plain></SENT>
<SENT sid="34" pm="."><plain>CTHRC1 was found to be expressed in 16 out of 19 types of human solid tumors including invasive melanoma but not in benign nevus and non-invasive melanoma [9]. </plain></SENT>
<SENT sid="35" pm="."><plain>However, the functional role of CTHRC1 in HCC and other cancers is still uncharacterized. </plain></SENT>
<SENT sid="36" pm="."><plain>In the present report, we show that CTHRC1 plays an important role in migration and invasion of hepatocellular carcinoma and that overexpression of CTHRC1 predicts poor prognosis in patients with HCC. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="s2"><title><text><SENT sid="37" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="s2a"><title><text><SENT sid="38" pm="."><plain>Ethics Statement </plain></SENT>
</text></title><p><text><SENT sid="39" pm="."><plain>All experimental procedures were undertaken at the National Taiwan University Hospital. </plain></SENT>
<SENT sid="40" pm="."><plain>The study was undertaken on project license number 201107042RC which was approved by the Ethics Committee of the National Taiwan University Hospital. </plain></SENT>
<SENT sid="41" pm="."><plain>The live participants had provided written informed consents. </plain></SENT>
<SENT sid="42" pm="."><plain>In addition, the written informed consent was obtained from the parents on the behalf of a teenager participant involved in our study. </plain></SENT>
<SENT sid="43" pm="."><plain>The need for written informed consent from the deceased participants and the next of kin of the deceased participants was waived by the Ethics Committee of the National Taiwan University Hospital. </plain></SENT>
</text></p></sec><sec id="s2b"><title><text><SENT sid="44" pm="."><plain>Liver Samples </plain></SENT>
</text></title><p><text><SENT sid="45" pm="."><plain>From 1982 to 1998, unifocal, primary HCCs surgically resected from 201 patients who received detailed pathological assessment and regular follow-up at the National Taiwan University Hospital were selected for this study. </plain></SENT>
<SENT sid="46" pm="."><plain>All the specimens were rendered anonymous and evaluated in a blinded manner. </plain></SENT>
<SENT sid="47" pm="."><plain>The patients included 157 men and 44 women with a mean age of 55.1 years (range, 8–88). </plain></SENT>
<SENT sid="48" pm="."><plain>Serum hepatitis B surface antigen (HBsAg) was detected in 142 cases and anti-hepatitis C (HCV) antibody in 56, including 18 positive for both. </plain></SENT>
<SENT sid="49" pm="."><plain>Liver cirrhosis was found in 88 cases (43.8%). </plain></SENT>
<SENT sid="50" pm="."><plain>None had received transhepatic arterial embolization or chemotherapy before tumor resection. </plain></SENT>
<SENT sid="51" pm="."><plain>After surgery, all patients received laboratory examinations such as serum α-fetoprotein (AFP) at 1–6 month intervals, and ultrasonography of liver at 3–12 month intervals. </plain></SENT>
<SENT sid="52" pm="."><plain>In all, 154 patients died within 10 years. </plain></SENT>
<SENT sid="53" pm="."><plain>Follow-up periods for survivors were 27–248 months (median, 142). </plain></SENT>
</text></p></sec><sec id="s2c"><title><text><SENT sid="54" pm="."><plain>Histology Study and Tumor Staging </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>Surgically resected specimens were formalin-fixed, paraffin embedded, and cut into sections (5-µm thick). </plain></SENT>
<SENT sid="56" pm="."><plain>The sections were stained with hematoxylin and eosin and reviewed by one of the authors (H.C. </plain></SENT>
<SENT sid="57" pm="."><plain>H.) to determine tumor grade and stage. </plain></SENT>
<SENT sid="58" pm="."><plain>The tumor grade was based on the criteria proposed by Edmonson and Steiner [10]. </plain></SENT>
<SENT sid="59" pm="."><plain>The tumors were staged according to American Joint Commission on Cancer system [11]. </plain></SENT>
<SENT sid="60" pm="."><plain>The margins of surgical specimens were inked and checked under a microscope. </plain></SENT>
<SENT sid="61" pm="."><plain>Only completely resected specimens were included in this study. </plain></SENT>
</text></p></sec><sec id="s2d"><title><text><SENT sid="62" pm="."><plain>Microarray Analysis </plain></SENT>
</text></title><p><text><SENT sid="63" pm="."><plain>Total RNA was isolated from paired specimens of tumor and non-tumorous liver parenchyma using TRIzol (Life Technologies, Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. </plain></SENT>
<SENT sid="64" pm="."><plain>The complementary DNA was labeled with Cy3-dCTP or Cy5-dCTP, and then applied to a microarray chip. </plain></SENT>
<SENT sid="65" pm="."><plain>The microarray experiment and data analysis were done by Welgene Biotech Company (Taipei, Taiwan) using the Agilent Oligo Chip (Human 1A Oligo Chip V2). </plain></SENT>
<SENT sid="66" pm="."><plain>Microarrays were scanned by laser scanner and the microarray signal intensities were measured to identify gene expression differences. </plain></SENT>
<SENT sid="67" pm="."><plain>The microarray data were deposited in the Gene expression Omnibus database (GEO accession number: GSE46408). </plain></SENT>
</text></p></sec><sec id="s2e"><title><text><SENT sid="68" pm="."><plain>RNA Isolation and Real Time RT-PCR </plain></SENT>
</text></title><p><text><SENT sid="69" pm="."><plain>Total RNA was isolated from tissue samples and cell lines using the Trizol reagent. </plain></SENT>
<SENT sid="70" pm="."><plain>The SYBR green-based real time reverse transcription-polymerase chain reaction (RT-PCR) assay was used to determine the mRNA level of CTHRC1 in the paired HCC and non-tumorous liver tissue samples using the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). </plain></SENT>
<SENT sid="71" pm="."><plain>Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a housekeeping gene, served as a control for RNA quantity. </plain></SENT>
<SENT sid="72" pm="."><plain>The primers for CTHRC1 were CTHRC1-F (5′-GCATGCTGTCAGCGTTGGTA-3′) and CTHRC1-R (5′-TCAATGGGAAGAGGTCCTGAA-3′). </plain></SENT>
<SENT sid="73" pm="."><plain>The primers used for GAPDH were GAPDH-F (5′-AGCCTCAAGATCATCAGCAATGCC-3′) and GAPDH-R (5′-TGTGGTCATGAGTCCTTCCACGAT-3′). </plain></SENT>
<SENT sid="74" pm="."><plain>In a volume of 20 µl PCR reaction, 1 µl of complementary DNA template was mixed with 10 µl of 2× Power SYBR® PCR master mix (Applied Biosystems), 200 nM of paired primers, and distilled water. </plain></SENT>
<SENT sid="75" pm="."><plain>PCR amplification included initial incubation at 50°C for 2 min, denaturing at 95°C for 10 min, and 40 cycles of denaturing at 95°C for 15 s and annealing at 60°C for 1 min. </plain></SENT>
<SENT sid="76" pm="."><plain>Receiver operating characteristic (ROC) analysis was used to select the optimal cut-off point for statistical analysis. </plain></SENT>
</text></p></sec><sec id="s2f"><title><text><SENT sid="77" pm="."><plain>Cell Culture and Treatment </plain></SENT>
</text></title><p><text><SENT sid="78" pm="."><plain>Huh7 and 293T cells were purchased from the American Type Culture Collection. </plain></SENT>
<SENT sid="79" pm="."><plain>GP2-293 cells were purchased from Clontech Inc. </plain></SENT>
<SENT sid="80" pm="."><plain>HA22T cells were purchased from Bioresource Collection and Research Center of Taiwan. </plain></SENT>
<SENT sid="81" pm="."><plain>All the cells were grown in DMEM with 10% fetal bovine serum. </plain></SENT>
<SENT sid="82" pm="."><plain>All the cells were grown at 37°C in a humidified atmosphere composed of 95% air and 5% CO2. </plain></SENT>
<SENT sid="83" pm="."><plain>The cells were passaged with trypsin/EDTA at 80?90% confluence. </plain></SENT>
<SENT sid="84" pm="."><plain>Untagged recombinant human CTHRC1 protein generated by wheat-germ cell free protein expression system was purchased from Abnova (Taipei, Taiwan). </plain></SENT>
<SENT sid="85" pm="."><plain>For the inhibition of ROCK activity, Huh7 cells were pretreated with a ROCK inhibitor Y27623 (5 µmol/L) for 1 h, and then treated with recombinant CTHRC1 (100 ng/ml) for 30 min. </plain></SENT>
</text></p></sec><sec id="s2g"><title><text><SENT sid="86" pm="."><plain>Plasmid, Transfection, and Retroviral Infection </plain></SENT>
</text></title><p><text><SENT sid="87" pm="."><plain>The open reading frame of CTHRC1 was amplified from HeLa cells by RT-PCR using the primers: CTHRC1-F: ATAAGAATGCGGCCGCTCCACCATGCGACCCCA and CTHRC1-R: GCGTCGACTTTTGGTAGTTCTTCAATAATG. </plain></SENT>
<SENT sid="88" pm="."><plain>The PCR products were cloned to pCMV-Tag 4A (Stratagene, La Jolla, CA) and subcloned into a retroviral expression vector pQCXIP (Clontech, Mountain View, CA) to generate pQCXIP-CTHRC1. </plain></SENT>
<SENT sid="89" pm="."><plain>pQCXIP-CTHRC1 was cotransfected with pVSV-G (Clontech) into the retroviral package cell GP2-293 to produce retrovirus. </plain></SENT>
<SENT sid="90" pm="."><plain>After incubating with medium containing retroviral particles and 8 µg/ml polybrene (Sigma-Aldrich, St. Louis, MO) for two days, the target cells were treated with puromycin (2 µg/ml) (Clontech) for two weeks to select the cells with stably integrated retroviral vectors. </plain></SENT>
</text></p></sec><sec id="s2h"><title><text><SENT sid="91" pm="."><plain>RNA Interference </plain></SENT>
</text></title><p><text><SENT sid="92" pm="."><plain>To knockdown the expression of CTHRC1, CTHRC1 shRNA in a lentiviral plasmid and control LacZ shRNA were purchased from the National RNAi Core Facility (Academia Sinica, Taipei, Taiwan). </plain></SENT>
<SENT sid="93" pm="."><plain>The target sequences were as follows: shCTHRC1-1: GCGTTGGTATTTCACATTC; shCTHRC1-2: CGGGATGGATTCAAAGGAG; shCTHRC1-3: CGCATCATTATTGAAGAAC; shCTHRC1-4: CCTGTATAATGGAATGTGC; shCTHRC1-5: GTGAAGGAATTGGTGCTGG. </plain></SENT>
<SENT sid="94" pm="."><plain>The lentivirus packaging, infection, and selection were performed as previously described [12]. </plain></SENT>
</text></p></sec><sec id="s2i"><title><text><SENT sid="95" pm="."><plain>Generation of Mouse Polyclonal Antibodies Against CTHRC1 Protein </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>The full-length open reading frame of CTHRC1 was amplified by PCR and cloned into expression vector pET32a (Merck, Darmstadt, Germany). </plain></SENT>
<SENT sid="97" pm="."><plain>The recombinant His-tagged CTHRC1 protein produced from Escherichia coli was purified on a Ni Sepharose 6 Fast Flow column (GE Healthcare, Uppsala, Sweden), injected subcutaneously into mice, and boosted for three times to generate polyclonal antibodies. </plain></SENT>
</text></p></sec><sec id="s2j"><title><text><SENT sid="98" pm="."><plain>Western Blot </plain></SENT>
</text></title><p><text><SENT sid="99" pm="."><plain>Protein samples (60 µg each) were separated by 10% SDS-PAGE and then electrotransferred onto nitrocellulose membranes (Amersham, Buckinghamshire, UK). </plain></SENT>
<SENT sid="100" pm="."><plain>The membranes were then exposed to primary and secondary antibodies at optimum dilution, and the immunoreactive signals detected with Immobilon Western Chemiluminescent HRP Substrate (Millipore, Bedford, MA). </plain></SENT>
<SENT sid="101" pm="."><plain>The primary antibodies were to CTHRC1 (1∶1000; home-made, mouse polyclonal), phosphorylated FAK at Tyr576/577(p-FAK576/577; 1∶1000; Cell Signaling, Beverly, MA), phosphorylated FAK at Tyr397(p-FAK397; 1∶1000; Cell Signaling, Beverly, MA), FAK (1∶2000; Cell Signaling), RhoA (1∶1500; Cell Signaling), Rac1 (1∶1000; Cell Signaling), Cdc42 (1∶1000; Cell Signaling), Myosin light chain 2 (MLC2) (1∶1000; Cell Signaling), phosphorylated MLC2 at Thr18/Ser19 (p-MLC2; 1∶1000; Cell Signaling), integrin β1 (1∶2000; Cell Signaling), and α-actin (1∶4000; Sigma-Aldrich). </plain></SENT>
</text></p></sec><sec id="s2k"><title><text><SENT sid="102" pm="."><plain>Detection of CTHRC1 in Culture Medium </plain></SENT>
</text></title><p><text><SENT sid="103" pm="."><plain>The proteins in culture medium were concentrated by the methanol/chloroform protein precipitation method [13]. </plain></SENT>
<SENT sid="104" pm="."><plain>Briefly, 800 µl of methanol followed by 200 µl of chloroform were added to 200 µl culture medium and mixed thoroughly by vortexing. </plain></SENT>
<SENT sid="105" pm="."><plain>Then 600 µl of ultrapure water was added and mixed well by vortexing. </plain></SENT>
<SENT sid="106" pm="."><plain>After centrifuging at 14,000 × g for 5 min, the upper aqueous layer was removed. </plain></SENT>
<SENT sid="107" pm="."><plain>600 µl of methanol was added and mixed by vortexing. </plain></SENT>
<SENT sid="108" pm="."><plain>After pelleting the proteins by centrifuging at 14,000 × g for 5 min, the methanol/chloroform mixture was removed. </plain></SENT>
<SENT sid="109" pm="."><plain>The pellets were dissolved in loading buffer, and the protein levels were determined by western blotting. </plain></SENT>
</text></p></sec><sec id="s2l"><title><text><SENT sid="110" pm="."><plain>Cell Proliferation Assay </plain></SENT>
</text></title><p><text><SENT sid="111" pm="."><plain>Cell survival and proliferation was measured using MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl-2H-tetrazolium bromide) assay. </plain></SENT>
<SENT sid="112" pm="."><plain>Cells (2000 per well) were seeded into 96-well plates, and incubated at 37°C in a humidified atmosphere with 5% CO2. </plain></SENT>
<SENT sid="113" pm="."><plain>At the appropriate time interval, MTT (2 mg/ml in PBS) was added and incubated for 4 h. </plain></SENT>
<SENT sid="114" pm="."><plain>The resulted color reaction product, MTT formazan, was extracted with dimethyl sulfoxide and the absorbance at 570 nm measured using a microplate reader. </plain></SENT>
</text></p></sec><sec id="s2m"><title><text><SENT sid="115" pm="."><plain>Tumorigenicity Assay </plain></SENT>
</text></title><p><text><SENT sid="116" pm="."><plain>NOD/SCID mice (female, 4–6 weeks old) were purchased from the National Taiwan University Laboratory Animal Center and accommodated for 7 days for environmental adjustment prior to experimentation. </plain></SENT>
<SENT sid="117" pm="."><plain>Cells were trypsinized, resuspended in serum-free DMEM, and injected subcutaneously (2×106 cells in a total volume 0.1 ml) into both flanks. </plain></SENT>
<SENT sid="118" pm="."><plain>Animals were observed weekly for tumour development for 5 to 8 weeks. </plain></SENT>
<SENT sid="119" pm="."><plain>The final tumor weights at the time of animal sacrifice were recorded. </plain></SENT>
<SENT sid="120" pm="."><plain>The animal experiments were approved by the Committee on Animal Research of National Taiwan University. </plain></SENT>
</text></p></sec><sec id="s2n"><title><text><SENT sid="121" pm="."><plain>Boyden Chamber Assay </plain></SENT>
</text></title><p><text><SENT sid="122" pm="."><plain>For invasion assays, we used modified Boyden chambers with filter inserts (pore size, 8 µm) coated with Matrigel (30 µg; Collaborative Biomedical Products, Bedford, MA) in 24-well tissue culture plates (Nucleopore, Pleasanton, CA). </plain></SENT>
<SENT sid="123" pm="."><plain>Cells (2×104) in 100 µl of serum-free DMEM were placed in the upper chamber, and 0.5 ml of DMEM containing 10% FBS was placed in the lower chamber. </plain></SENT>
<SENT sid="124" pm="."><plain>After 24 h in culture, cells were fixed in 3.7% formaldehyde in PBS for 15 min and then stained with 4′-6-diamidino-2- phenylindole (DAPI) in 0.1% Triton X-100 containing PBS for 15 min. </plain></SENT>
<SENT sid="125" pm="."><plain>Cells on the upper side of the filters were removed with cotton-tipped swabs, and the filters were washed with PBS. </plain></SENT>
<SENT sid="126" pm="."><plain>Cells on the underside of the filters were viewed and counted under a fluorescence microscope. </plain></SENT>
<SENT sid="127" pm="."><plain>Each group was plated in triplicate in each experiment, and each experiment was repeated three times. </plain></SENT>
<SENT sid="128" pm="."><plain>The cell motility assay was done in the same way as invasion assay except the filters were not coated with Matrigel and the incubation time was 20 h. </plain></SENT>
</text></p></sec><sec id="s2o"><title><text><SENT sid="129" pm="."><plain>Scratch Wound Assay </plain></SENT>
</text></title><p><text><SENT sid="130" pm="."><plain>HA22T cells were grown to confluence in six-well culture plates. </plain></SENT>
<SENT sid="131" pm="."><plain>Cell layers were scraped with a sterile pipette tip and reincubated at 37°C. </plain></SENT>
<SENT sid="132" pm="."><plain>Photographs were taken at indicated time points. </plain></SENT>
<SENT sid="133" pm="."><plain>Migration from the edge of the injured monolayer was quantified by measurement of the distance between the wound edges. </plain></SENT>
<SENT sid="134" pm="."><plain>Experiments were done in triplicate and repeated twice. </plain></SENT>
</text></p></sec><sec id="s2p"><title><text><SENT sid="135" pm="."><plain>Adhesion Assay </plain></SENT>
</text></title><p><text><SENT sid="136" pm="."><plain>Cells (1×104 cells per well) were seeded onto 96-well plates coated with 20 µg/ml fibronectin (Sigma-Aldrich). </plain></SENT>
<SENT sid="137" pm="."><plain>After incubated at 37°C for the indicated period, the cells were washed with PBS 3 times, fixed with 3.7% formaldehyde, and stained with crystal violet. </plain></SENT>
<SENT sid="138" pm="."><plain>The adherent cells were counted under a microscope. </plain></SENT>
</text></p></sec><sec id="s2q"><title><text><SENT sid="139" pm="."><plain>Immunofluorescence Staining </plain></SENT>
</text></title><p><text><SENT sid="140" pm="."><plain>Cells were trypsinized, replated onto 20 µg/ml fibronectin coated slides, and incubated at 37°C for 60 min, Cells were fixed with 4% paraformaldehyde in PBS for 10 min, permeabilized in 0.5% Triton X-100 at room temperature for 5 min, and blocked with blocking solution (0.5% FBS and 0.1% Triton X-100 in PBS). </plain></SENT>
<SENT sid="141" pm="."><plain>Cells were stained with mouse anti-vinculin antibody (1∶400; Thermo Fisher Scientific, Waltham, MA) in blocking solution for 2 h, washed with PBS 3 times, and then incubated with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse secondary antibody (1∶1000; Alexa Fluor 488; Life Technologies) and rhodamine-phalloidin (1∶500; Life Technologies) for 1 h. </plain></SENT>
<SENT sid="142" pm="."><plain>Cells were washed, mounted, and observed under a fluorescence microscope. </plain></SENT>
</text></p></sec><sec id="s2r"><title><text><SENT sid="143" pm="."><plain>3D Collagen Gel Invasion Assay </plain></SENT>
</text></title><p><text><SENT sid="144" pm="."><plain>Cells (104 per well) were resuspended in collagen gel mixture (70 µl of 3 mg/ml rat tail collagen I, 9 µl of 10x DMEM, 2 µl of 0.2 M HEPES pH 7.3, 8 µl of H2O, with the pH value adjusted to around 7.4 with 5 N NaOH) and seeded onto 96-well plates. </plain></SENT>
<SENT sid="145" pm="."><plain>The gel was incubated 30 min at 37°C to solidify, and then supplemented with 100 µl of DMEM containing 1% FBS, incubated 3 days, observed for change in cell-spreading phenotype, and photographed using an inverted photomicroscope. </plain></SENT>
</text></p></sec><sec id="s2s"><title><text><SENT sid="146" pm="."><plain>Rho Protein Activation Assay </plain></SENT>
</text></title><p><text><SENT sid="147" pm="."><plain>RhoA, Rac1, and Cdc42 activities in cells were measured using Rho protein activation assay kits (Cytoskeleton, Denver, CO) according to the manufacturer’s instructions. </plain></SENT>
<SENT sid="148" pm="."><plain>CTHRC1-knocked down HA22T cells were seeded in 100-mm dishes, cultured to 40–60% confluence, and serum-starved overnight. </plain></SENT>
<SENT sid="149" pm="."><plain>After stimulated with 10% FBS for 30 min at 37°C, the cells are washed with ice cold PBS, and lysed with cell lysis buffer. </plain></SENT>
<SENT sid="150" pm="."><plain>Lysates were harvested by centrifugation at 10,000 rpm for 2 min and assayed to determine protein concentration using a protein assay kit (BioRad, Richmond, CA). </plain></SENT>
<SENT sid="151" pm="."><plain>In pull-down assays, equal amounts of protein from cell lysates were incubated for 2 h at 4°C with 50 µg of Rhotekin-RBD or PAK-PBD protein agarose beads. </plain></SENT>
<SENT sid="152" pm="."><plain>Pellets were washed and subjected to western blotting using anti-RhoA, rabbit anti-Rac1, and Cdc42 antibodies. </plain></SENT>
</text></p></sec><sec id="s2t"><title><text><SENT sid="153" pm="."><plain>Statistical Analysis </plain></SENT>
</text></title><p><text><SENT sid="154" pm="."><plain>The data analyses were carried out using MedCalc (MedCalc Software, Mariakerke, Belgium) software. </plain></SENT>
<SENT sid="155" pm="."><plain>Correlation between CTHRC1 expression and clinicopathologic parameters was evaluated using the χ2 test. </plain></SENT>
<SENT sid="156" pm="."><plain>Multivariant analyses were conducted by multiple Cox’s proportional hazards models Survival rates were calculated using the Kaplan-Meier method, and difference in survival curves was analyzed by using the log-rank test. </plain></SENT>
<SENT sid="157" pm="."><plain>Student’s t-test was used for comparisons of cell number, tumor weights, and luciferase values. </plain></SENT>
<SENT sid="158" pm="."><plain>Two-tailed P&lt;0.05 was considered statistically significant. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="s3"><title><text><SENT sid="159" pm="."><plain>Results </plain></SENT>
</text></title><sec id="s3a"><title><text><SENT sid="160" pm="."><plain>CTHRC1 is Overexpressed in HCC </plain></SENT>
</text></title><p><text><SENT sid="161" pm="."><plain>Using microarray analysis for six pairs of HCC and corresponding nontumorous liver parenchyma, we found the CTHRC1 gene was overexpressed in three of the six HCCs. </plain></SENT>
<SENT sid="162" pm="."><plain>Semi-quantitative RT-PCR was employed for measurement of CTHRC1 mRNA expression in paired HCC and nontumorous liver parenchyma and showed overexpression of CTHRC1 in 4 of 8 HCCs (Figure 1A). </plain></SENT>
<SENT sid="163" pm="."><plain>To further confirm that CTHRC1 is overexpressed in HCC, the protein levels of CTHRC1 in HCC tissue samples were analyzed by western blotting. </plain></SENT>
<SENT sid="164" pm="."><plain>As shown in Figure 1B, CTHRC1 was overexpressed in 5 of the 8 HCC specimens, but not in nontumourous liver parenchyma. </plain></SENT>
<SENT sid="165" pm="."><plain>To determine the clinicopathological significance of CTHRC1 expression, 201 unifocal HCCs were analyzed by quantitative RT-PCR. </plain></SENT>
<SENT sid="166" pm="."><plain>An ROC curve demonstrated that ΔCt value of 8.48 was the optimal cutoff point for predicting patient death within four years after operation. </plain></SENT>
<SENT sid="167" pm="."><plain>The area under curve (AUC) was 0.621 (Figure S1). </plain></SENT>
<SENT sid="168" pm="."><plain>Therefore, we segregated the tumors into CTHRC1-high (ΔCt &lt;8.48) and CTHRC1-low (ΔCt ≥8.48) groups. </plain></SENT>
<SENT sid="169" pm="."><plain>Using this cutoff point, CTHRC1 was overexpressed (ΔCt &lt;8.48) in 62 tumors (30.8%). </plain></SENT>
<SENT sid="170" pm="."><plain>In contrast, none of the 103 paired non-tumorous liver RNA samples available for examination overexpressed CTHRC1. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0070324-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0070324.g001</object-id><label>Figure 1</label><caption><title><text><SENT sid="171" pm="."><plain>Overexpression of CTHRC1 in HCC. </plain></SENT>
</text></title><p><text><SENT sid="172" pm="."><plain>(A) RT-PCR analysis showed overexpression of CTHRC1 in 4 of 8 HCC specimens (T), but in none of the 8 specimens of nontumorous liver parenchyma (N). </plain></SENT>
<SENT sid="173" pm="."><plain>S26 (ribosomal protein S26) served as internal control. </plain></SENT>
<SENT sid="174" pm="."><plain>(B) Western blotting showed CTHRC1 was expressed in 5 of 8 HCC specimens (T) but not in nontumourous liver parenchyma (N). </plain></SENT>
<SENT sid="175" pm="."><plain>(C, D) Cumulative overall (C) and disease-free (D) survival curves for 201 patients with resected, unifocal, primary HCC stratified by CTHRC1 mRNA expression level as determined by real time RT-PCR. </plain></SENT>
<SENT sid="176" pm="."><plain>Patients with HCCs overexpressing the CTHRC1 gene had significantly lower 10-year overall and disease-free survival rates than those with HCCs without CTHRC1 overexpression. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0070324.g001"/></fig></SecTag><p><text><SENT sid="177" pm="."><plain>To elucidate the role of CTHRC1 in HCC progression, we evaluated the correlation of CTHRC1 expression with a variety of clinicopathologic factors. </plain></SENT>
<SENT sid="178" pm="."><plain>As shown in Table 1, CTHRC1 expression correlated with large tumor size (&gt;5 cm; P = 0.008) but not with sex, age, HBsAg status, α-fetoprotein (AFP) level, tumor grade, p53 mutation, and β-catenin mutation. </plain></SENT>
<SENT sid="179" pm="."><plain>Importantly, CTHRC1 was expressed much more frequently in advanced stage (stage II-III) HCCs than in early-stage HCCs (stage I) (P = 0.014). </plain></SENT>
<SENT sid="180" pm="."><plain>Compared to those with CTHRC1-low HCCs, patients with CTHRC1-high HCCs had a lower 10-year overall and disease-free survival rates (Figure 1C and D). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0070324-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0070324.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="181" pm="."><plain>Correlation of CTHRC1 expression and clinicopathological factors. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0070324-t001-1" xlink:href="pone.0070324.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1"><text><SENT sid="182" pm="."><plain>CTHRC1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>Odds ratio </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>P value </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>+ (n = 62) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>− (n = 139) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>(95% CI) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>Age (year) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>&lt; = 55 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>30 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>59 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>1.27(0.67–2.42) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>NS </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>&gt;55 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>32 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>80 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>Sex </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>Male </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>48 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>109 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>0.94(0.43–2.06) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>NS </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>Female </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>14 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>30 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>HBsAg </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>(−) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>17 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>34 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>1.11(0.53–2.32) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>NS </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>(+) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>44 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>98 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>AFP (ng/mL) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>&lt;200 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>25 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>72 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>0.56(0.29–1.09) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>NS </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>&gt; = 200 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>37 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>60 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>Size (cm) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>&lt; = 5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>21 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>75 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>0.44(0.22–0.85) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>0.008 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>&gt;5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>41 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>64 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>Grade </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>1–2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>33 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>93 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>0.56(0.29–1.09) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>NS </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>3–4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>29 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>46 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>Stage </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>I </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>18 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>66 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>0.45(0.23-0.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>0.014 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>II–III </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>44 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>73 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>p53 mutation </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>(−) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>46 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>0.67(0.31–1.46) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>NS </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>(+) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>26 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>40 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>β-catenin mutation </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>(−) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>45 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>79 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>3.23(0.84–14.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>NS </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>(+) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>17 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap></SecTag><p><text><SENT sid="269" pm="."><plain>Among those parameters analyzed, high AFP level, large tumor size, high tumor grade, high tumor stage, CTHRC1 overexpression, p53 mutation, and absence of β-catenin mutation were significantly associated with poor prognosis in univariat analysis (Table 2). </plain></SENT>
<SENT sid="270" pm="."><plain>In multivariate analysis of prognostic factors, only tumor stage and CTHRC1 expression were significant and independent prognostic factors for HCC patients (Table 3). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0070324-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0070324.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="271" pm="."><plain>Univariate analysis of prognostic factors in patients with HCCs. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0070324-t002-2" xlink:href="pone.0070324.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>Variables </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>Hazards ration </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>95%CI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>Unfavorable/Favorable </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>P-value </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>Age (years) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>1.049 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>0.754–1.457 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>&gt;55/&lt; = 55 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>0.7776 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>Sex </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>1.134 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>0.772–1.666 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>Male/Female </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>0.5209 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>Size </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>2.023 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>1.446–2.831 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>&gt;5 cm/&lt; = 5 cm </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>0.0001* </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>AFP (ng/mL) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>1.645 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>1.182–2.289 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>&gt; = 200/&lt;200 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>0.0032* </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>CTHRC1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>1.632 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>1.160–2.296 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>High/Low </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>0.0049* </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>Grade </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>1.505 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>1.081–2.096- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>3,4/1,2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>0.0152* </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>Stage </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>2.950 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>2.073–5.198 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>II–III/I </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>&lt;0.0001* </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>p53 mutation </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>1.938 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>1.320–2.846 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>Positive/Negative </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>0.0007* </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>β-catenin mutation </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>2.097 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>1.206–3.697 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>Negative/Positive </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>0.0089* </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>*</label><p><text><SENT sid="322" pm="."><plain>P&lt;0.05. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="pone-0070324-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0070324.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="323" pm="."><plain>Multivariate analysis of prognostic factors in patients with HCCs. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0070324-t003-3" xlink:href="pone.0070324.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>Variables </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>Hazards ration </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>95%CI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>Unfavorable/Favorable </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>P-value </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>Multivariate analysis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>Size </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>1.0782 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>0.706–1.647 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>&gt;5 cm/&lt; = 5 cm </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>0.6070 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>AFP (ng/mL) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>1.104 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>0.722–1.690 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>&gt; = 200/&lt;200 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>0.6454 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>CTHRC1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>1.644 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>1.085–2.490 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>High/Low </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>0.0189* </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>Grade </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>1.232 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>0.825–1.838 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>3,4/1,2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>0.3077 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>Stage </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>2.717 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>1.671–4.417 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>II–III/I </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>0.0001* </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>p53 mutation </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>1.516 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>0.997–2.306 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>Positive/Negative </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>0.0517 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>β-catenin mutation </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>1.043 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>0.549–1.982 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>Negative/Positive </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>0.8969 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label>*</label><p><text><SENT sid="365" pm="."><plain>P&lt;0.05. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s3b"><title><text><SENT sid="366" pm="."><plain>CTHRC1 Promotes Tumor Migration and Invasion </plain></SENT>
</text></title><p><text><SENT sid="367" pm="."><plain>In HCC, advanced stage is characterized by vascular invasion and various degrees of intrahepatic metastasis. </plain></SENT>
<SENT sid="368" pm="."><plain>Since CTHRC1 overexpression in HCC is associated with advanced stage, we speculated that CTHRC1 may play a role in tumor growth and invasion. </plain></SENT>
<SENT sid="369" pm="."><plain>To test this hypothesis, we evaluated the expression of CTHRC1 in HCC cell lines and found that HA22T and Huh7 cells had the highest and lowest CTHRC1 expression, respectively. </plain></SENT>
<SENT sid="370" pm="."><plain>So we selected them for further study. </plain></SENT>
<SENT sid="371" pm="."><plain>Five different lentiviral constructs carrying CTHRC1 shRNAs were used to transduce HCC cell line HA22T. </plain></SENT>
<SENT sid="372" pm="."><plain>Cells transduced with shRNAs #1and #5 resulted in a dramatic reduction of CTHRC1 mRNA and protein expression (Figure 2A) and the amount of CTHRC1 in the culture medium (Figure 2B) and were selected for subsequent studies. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0070324-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0070324.g002</object-id><label>Figure 2</label><caption><title><text><SENT sid="373" pm="."><plain>CTHRC1 promotes tumor migration and invasion. </plain></SENT>
</text></title><p><text><SENT sid="374" pm="."><plain>(A) shRNA#1 and #5 markedly reduced CTHRC1 mRNA and protein in HA22T cells. </plain></SENT>
<SENT sid="375" pm="."><plain>(B) Knockdown of CTHRC1 markedly decreased the amount of CTHRC1 in the culture medium. </plain></SENT>
<SENT sid="376" pm="."><plain>(C) Depletion of CTHRC1 did not affect proliferation, as measured by MTT assay. </plain></SENT>
<SENT sid="377" pm="."><plain>(D–E) Knockdown of CTHRC1 in HA22T cells inhibited invasion (D) through Matrigel and motility (E). </plain></SENT>
<SENT sid="378" pm="."><plain>(F) Scratch wound assay. </plain></SENT>
<SENT sid="379" pm="."><plain>Knockdown of CTHRC1 in HA22T cells delayed closure of scratch wounds Photographs were taken at 30 h. </plain></SENT>
<SENT sid="380" pm="."><plain>(G) Overexpression of CTHRC1 in Huh7 increased the amount of CTHRC1 in the culture medium. </plain></SENT>
<SENT sid="381" pm="."><plain>(H) Overexpression of CTHRC1 in Huh7 cells enhanced tumor invasion through Matrigel. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0070324.g002"/></fig></SecTag><p><text><SENT sid="382" pm="."><plain>We first tested the effect of CTHRC1 knockdown on cell proliferation. </plain></SENT>
<SENT sid="383" pm="."><plain>MTT assay showed that knockdown of CTHRC1 had no effect on cell survival and proliferation (Figure 2C). </plain></SENT>
<SENT sid="384" pm="."><plain>When injected into NOD/SCID mice, HA22T cells with or without CTHRC1 knockdown cannot form tumor up to 8 weeks after injection (data not shown). </plain></SENT>
<SENT sid="385" pm="."><plain>Overexpression of CTHRC1 in Huh7 cells did not enhance tumor growth in NOD/SCID mice (Figure S2). </plain></SENT>
<SENT sid="386" pm="."><plain>These results indicate that CTHRC1 does not promote growth of HCC. </plain></SENT>
</text></p><p><text><SENT sid="387" pm="."><plain>In the modified Boyden chamber assay, knockdown of CTHRC1 dramatically inhibited tumor invasion (Figure 2D). </plain></SENT>
<SENT sid="388" pm="."><plain>To elucidate the mechanism of this inhibition, a transwell migration assay was performed and showed similar reduction in the number of migrating cells, indicating the reduction in invasive capacity is mainly due to reduced cell migration (Figure 2E). </plain></SENT>
<SENT sid="389" pm="."><plain>Scratch wound assay also showed that closure of the wound was delayed in CTHRC1-knocked down HA22T cells, further confirming the effect of CTHRC1 on tumor cell migration (Figure 2F). </plain></SENT>
<SENT sid="390" pm="."><plain>On the other hand, when CTHRC1 was overexpressed in Huh7 cells by retroviral transduction (Figure 2G), invasiveness of the tumor cells was enhanced (Figure 2H). </plain></SENT>
<SENT sid="391" pm="."><plain>To confirm the role of CTHRC1 in tumor invasion, cells were grown in a 3-D gel consisting of a thick matrix of native collagen type I fibers. </plain></SENT>
<SENT sid="392" pm="."><plain>After incubation for 3-days, multiple long protrusions could be seen in parental cells and control shRNA transduced cells but not in CTHRC1-knocked down cells (Figure 3). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0070324-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0070324.g003</object-id><label>Figure 3</label><caption><title><text><SENT sid="393" pm="."><plain>CTHRC1 activates RhoA activity. </plain></SENT>
</text></title><p><text><SENT sid="394" pm="."><plain>(A) Pull-down assay of Rho family proteins showed that knockdown of CTHRC1 inhibited the activation of RhoA, but not Rac1 or Cdc42. </plain></SENT>
<SENT sid="395" pm="."><plain>(B) Treating Huh7 cells with recombinant CTHRC1 (100 ng/ml) activated the RhoA pathway. </plain></SENT>
<SENT sid="396" pm="."><plain>(C) CTHRC1 enhanced phosphorylation of MLC2, a target of ROCK. </plain></SENT>
<SENT sid="397" pm="."><plain>(D) Pretreatment with a ROCK inhibitor Y2732 (5 µmol/L) abolished the invasion-promoting activity of CTHRC1. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0070324.g003"/></fig></SecTag></sec><sec id="s3c"><title><text><SENT sid="398" pm="."><plain>CTHRC1 Promotes Cell Migration by Activation of RhoA </plain></SENT>
</text></title><p><text><SENT sid="399" pm="."><plain>The Rho family of small GTPase regulates cell motility by orchestrating reorganization of the cytoskeleton [14]. </plain></SENT>
<SENT sid="400" pm="."><plain>Their participation in the process of tumor (e.g., HCC) invasion and metastasis has been suggested [15]. </plain></SENT>
<SENT sid="401" pm="."><plain>Therefore, it was of interest to determine whether GTP-binding proteins of the Rho family are involved in CTHRC1-mediated invasion of HCC cells. </plain></SENT>
<SENT sid="402" pm="."><plain>As shown in Figure 3A, knockdown of CTHRC1 decreased the activity of RhoA (relative amount of RhoA in the active GTP-binding form) but not of the two other Rho-family small GTPases, Rac1 and Cdc42, in HA22T cells. </plain></SENT>
<SENT sid="403" pm="."><plain>On the other hand, overexpression of CTHRC1 in Huh7 cells increased the activity of RhoA but not that of Rac1 and Cdc42 (Figure 3B). </plain></SENT>
<SENT sid="404" pm="."><plain>Treating Huh7 cells with recombinant CTHRC1 also enhanced RhoA activity (Figure 3C). </plain></SENT>
<SENT sid="405" pm="."><plain>ROCK is a kinase associated with and activated by GTP-bound form of RhoA for transducing RhoA signaling [16]. </plain></SENT>
<SENT sid="406" pm="."><plain>CTHRC1 treatments induced phosphorylation of MLC2, a ROCK target (Figure 3D). </plain></SENT>
<SENT sid="407" pm="."><plain>The enhanced phosphorylation of MLC2 by CTHRC1 was abolished by 5 µmol/L Y27632, a ROCK inhibitor (Figure 3E). </plain></SENT>
<SENT sid="408" pm="."><plain>The invasion-promoting activity of CTHRC1 was inhibited by Y27632 treatment (Figure 3F). </plain></SENT>
<SENT sid="409" pm="."><plain>Taken together, these data suggest that CTHRC1 promotes tumor invasion by activating RhoA/ROCK pathway. </plain></SENT>
</text></p></sec><sec id="s3d"><title><text><SENT sid="410" pm="."><plain>CTHRC1 Promotes Cell-matrix Adhesion by Enhancing Integrin β1 Expression </plain></SENT>
</text></title><p><text><SENT sid="411" pm="."><plain>Cell-matrix adhesion is an important step in cell migration. </plain></SENT>
<SENT sid="412" pm="."><plain>So we compared the adhesive capability of HA22T cells before knockdown of CTHRC1 with that of the same cells after knockdown. </plain></SENT>
<SENT sid="413" pm="."><plain>Cells were detached with trypsin-EDTA and plated on fibronectin-coated coverslips in medium for 30 min. </plain></SENT>
<SENT sid="414" pm="."><plain>After washing, the adherent cells in five random fields were counted under a light microscope. </plain></SENT>
<SENT sid="415" pm="."><plain>As shown in Figure 4A, compared with the number of adhering parental cells and vector-control cells, the number of adherent CTHRC1 knocked-down cells was significantly decreased. </plain></SENT>
<SENT sid="416" pm="."><plain>Treating Huh7 cells with recombinant CTHRC1 enhanced adhesion to fibronectin (Figure 4B). </plain></SENT>
<SENT sid="417" pm="."><plain>Vinculin is a cytoskeletal protein that participates in cell adhesion and migration by linking the actin cytoskeleton to transmembrane receptors, integrin, and cadherin [17]. </plain></SENT>
<SENT sid="418" pm="."><plain>Immunofluorescence staining for vinculin after allowing the cells to adhere to fibronectin-coated coverslips for 60 min showed less spreading of cells with knockdown of CTHRC1 compared to control cells, and showed less well-developed focal adhesions (Figure 4C). </plain></SENT>
<SENT sid="419" pm="."><plain>Focal adhesion kinase (FAK), a nonreceptor tyrosine kinase, is an important positive regulator cell of spreading and migration [18]. </plain></SENT>
<SENT sid="420" pm="."><plain>FAK is activated by tyrosine autophosphorylation in response to integrin clustering achieved by cell adhesion [19]. </plain></SENT>
<SENT sid="421" pm="."><plain>As shown in Figure 4D and 4E, CTHRC1 induced phosphorylation of FAK at residues 576/577, whereas knockdown of CTHRC1 inhibited autophosphorylation of FAK. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0070324-g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0070324.g004</object-id><label>Figure 4</label><caption><title><text><SENT sid="422" pm="."><plain>CTHRC1 promotes cell adhesion through activation of integrin β1/FAK pathway. </plain></SENT>
</text></title><p><text><SENT sid="423" pm="."><plain>(A) Adhesion assay. </plain></SENT>
<SENT sid="424" pm="."><plain>Approximately 1×104 cells were seeded into fibronectin-coated 96-well plates and incubated at 37°C for 30 min, washed, fixed, and stained with crystal violet. </plain></SENT>
<SENT sid="425" pm="."><plain>The remaining cells were counted. </plain></SENT>
<SENT sid="426" pm="."><plain>Knockdown of CTHRC1 markedly reduced the number of cells adherent to fibronectin. </plain></SENT>
<SENT sid="427" pm="."><plain>(B) Treating Huh7 cells with CTHRC1 (100 ng/ml) enhanced adhesion to fibronectin at 15 min and 30 min. </plain></SENT>
<SENT sid="428" pm="."><plain>(C) Knockdown of CTHRC1 decreased the formation of focal adhesion structures. </plain></SENT>
<SENT sid="429" pm="."><plain>Cells were trypsinized and replated onto fibronectin-coated slides and incubated at 37°C for 60 min, fixed, and stained. </plain></SENT>
<SENT sid="430" pm="."><plain>Mouse anti-vinculin was used to visualize focal adhesions (upper panel), and rhodamine-phalloidin was used to visualize actin filaments (lower panel). </plain></SENT>
<SENT sid="431" pm="."><plain>(D) CTHRC1 treatment enhanced phosphorylation of FAK at residues 576/577. </plain></SENT>
<SENT sid="432" pm="."><plain>(E) Knockdown of CTHRC1 inhibited phosphorylation of FAK. </plain></SENT>
<SENT sid="433" pm="."><plain>(F) CTHRC1 enhanced expression of integrin β1. </plain></SENT>
<SENT sid="434" pm="."><plain>(G) The adhesion-promoting effect of CTHRC1 was abolished by integrin β1 blocking antibody. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0070324.g004"/></fig></SecTag><p><text><SENT sid="435" pm="."><plain>Integrin β1 mediates adhesion of cells with fibronectin [20]. </plain></SENT>
<SENT sid="436" pm="."><plain>CTHRC1 enhanced the expression of integrin β1 in Huh7 cells (Figure 4F). </plain></SENT>
<SENT sid="437" pm="."><plain>The adhesion-promoting effect of CTHRC1 was abolished by integrin β1 blocking antibody (Figure 4G), indicating CTHRC1 promotes cell adhesion through induction of integrin β1. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s4"><title><text><SENT sid="438" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="439" pm="."><plain>Cancer invasion and metastasis are complex processes involving increase in cell motility, adhesion to underlying stroma, digestion of extracellular matrix, vascular invasion, evasion of immune attack, and growth in foreign environments. </plain></SENT>
<SENT sid="440" pm="."><plain>Many mechanisms regulate these processes. </plain></SENT>
<SENT sid="441" pm="."><plain>One way to identify the genes involved in these processes is to compare the gene expression profile between tumor and nontumorous tissue [12], [21]. </plain></SENT>
<SENT sid="442" pm="."><plain>In the present study, we used genome-wide microarray analysis and identified CTHRC1 as another gene overexpressed in HCC. </plain></SENT>
<SENT sid="443" pm="."><plain>Overexpression of CTHRC1 was seen more frequently in larger and more advanced stage tumors. </plain></SENT>
<SENT sid="444" pm="."><plain>Besides, expression of CTHRC1 was an indicator of poor prognosis. </plain></SENT>
<SENT sid="445" pm="."><plain>These results suggest a functional role of CTHRC1 in tumor progression. </plain></SENT>
<SENT sid="446" pm="."><plain>Previous studies also found overexpression of CTHRC1 in melanoma and cancers of the gastrointestinal tract, lung, breast, ovary, and many other organs [9]). </plain></SENT>
<SENT sid="447" pm="."><plain>These observations indicate that CTHRC1 is commonly overexpressed in cancer. </plain></SENT>
</text></p><p><text><SENT sid="448" pm="."><plain>Cthrc1 was initially found in a screening for differentially expressed genes in balloon injured versus normal rat vessels [6]. </plain></SENT>
<SENT sid="449" pm="."><plain>Forced expression of Cthrc1 was found to promote migration of rat fibroblasts. </plain></SENT>
<SENT sid="450" pm="."><plain>So we speculated that cancer cells secrete CTHRC1 to promote their migration. </plain></SENT>
<SENT sid="451" pm="."><plain>Indeed, knockdown of CTHRC1 inhibited invasiveness of HCC cells in a transwell invasion assay. </plain></SENT>
<SENT sid="452" pm="."><plain>On the other hand, overexpression of CTHRC1 promoted tumor invasion. </plain></SENT>
<SENT sid="453" pm="."><plain>The enhanced invasiveness is mostly attributed to the increase in cell migration as demonstrated in the transwell migration assay and scratch wound assay. </plain></SENT>
<SENT sid="454" pm="."><plain>A similar promigratory role has been reported for melanoma [9]. </plain></SENT>
</text></p><p><text><SENT sid="455" pm="."><plain>It is still not clear how CTHRC1 regulates cancer cell migration. </plain></SENT>
<SENT sid="456" pm="."><plain>Pyagay et al. reported overexpression of Cthrc1 caused a dramatic reduction in the synthesis of collagen type I in rat fibroblasts [6], but we found no change in collagen synthesis in HA22T cells with knockdown of CTHRC1 (data not shown). </plain></SENT>
<SENT sid="457" pm="."><plain>So we decided to test the important signaling pathways involved in cell migration. </plain></SENT>
<SENT sid="458" pm="."><plain>The Rho family of small GTPase, including RhoA, Cdc42, and Rac1, are key regulators of cell migration based on their effects on the cytoskeletal reorganization and cell adhesion activities [15]. </plain></SENT>
<SENT sid="459" pm="."><plain>Therefore. we tested the activity of the Rho family proteins and found CTHRC1 specifically inhibits the activation of RhoA. </plain></SENT>
<SENT sid="460" pm="."><plain>Interestingly, CTHRC1 was reported to be an activator of the planar cell polarity pathway of Wnt signaling in mouse embryogenesis [8]. </plain></SENT>
<SENT sid="461" pm="."><plain>Planar cell polarity signaling regulates the establishment of polarity within the plane of the epithelium and allows cells to obtain directional information during embryogenesis [22]. </plain></SENT>
<SENT sid="462" pm="."><plain>One of the major components of the planar cell polarity pathway is the activation of small GTPases, including RhoA and Rac1, and their downstream protein kinases, ROCK and JNK, respectively, to regulate cytoskeletal reorganization [23]. </plain></SENT>
<SENT sid="463" pm="."><plain>Hence, by secreting CTHRC1 into its microenviroment, cancer cells stimulate their own motility and that of adjacent cancer cells by activating RhoA signaling. </plain></SENT>
</text></p><p><text><SENT sid="464" pm="."><plain>Activation of RhoA mediates the formation of stress fibers and the integrin adhesion complex to anchor cells to their substrata [24], [25]. </plain></SENT>
<SENT sid="465" pm="."><plain>Adhesion to stroma is essential for cell viability and migration. </plain></SENT>
<SENT sid="466" pm="."><plain>Our study found that CTHRC1 enhanced the ability of HCC cells to adhere to fibronectin-coated slides. </plain></SENT>
<SENT sid="467" pm="."><plain>Induction of integrin β1 expression and activation of FAK phosphorylation to promote focal adhesion formation may account for this effect. </plain></SENT>
</text></p><p><text><SENT sid="468" pm="."><plain>During preparation of this manuscript, Park et al. reported that CTHRC1 is overexpression in pancreatic cancer [26]. </plain></SENT>
<SENT sid="469" pm="."><plain>CTHRC1 promoted growth of pancreatic tumor and metastatic spread of cancer cells to distant organs. </plain></SENT>
<SENT sid="470" pm="."><plain>Besides, they also found overexpression of CTHRC1 in pancreatic cancer cells resulted in increased motility and adhesiveness. </plain></SENT>
<SENT sid="471" pm="."><plain>The similar effects of CTHRC1 in HCC and pancreatic cancer suggest that CTHRC1 is an important effector for tumor invasion. </plain></SENT>
<SENT sid="472" pm="."><plain>There are subtle differences between our results and theirs. </plain></SENT>
<SENT sid="473" pm="."><plain>We did not found CTHRC1 promotes growth of HCC cells. </plain></SENT>
<SENT sid="474" pm="."><plain>We found RhoA is the most important small GTPase for CTHRC1-mediated HCC invasion and they found Rac1 accounts for the invasiveness in pancreatic cancer. </plain></SENT>
<SENT sid="475" pm="."><plain>These observations indicate CTHRC1 may use similar but different mechanisms in different cells to promote tumor invasion. </plain></SENT>
</text></p><p><text><SENT sid="476" pm="."><plain>Since CTHRC1 is a secretory protein highly expressed in cancers, it is likely to be aberrantly expressed in the serum of cancer patients and may be considered a promising tumor marker. </plain></SENT>
<SENT sid="477" pm="."><plain>Besides, the functional role of CTHRC1 in cancer cell migration and adhesion suggests that blocking CTHRC1, such with neutralizing antibody, may inhibit tumor metastasis and therefore be therapeutically beneficial. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="s5"><title><text><SENT sid="478" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0070324.s001"><label>Figure S1</label><caption><p><text><SENT sid="479" pm="."><plain>The ROC curve for CTHRC1 expression and patient death within four years in HCC patients who underwent surgical resection. </plain></SENT>
</text></p><p><text><SENT sid="480" pm="."><plain>(TIF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0070324.s001.tif"><caption><p><text><SENT sid="481" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0070324.s002"><label>Figure S2</label><caption><p><text><SENT sid="482" pm="."><plain>CTHRC1 expression did not affect the growth rate of Huh7 cells in NOD/SCID mice. 2×106 Huh7 cells were trypsinized, resuspended in serum-free DMEM, and injected subcutaneously into flanks. </plain></SENT>
<SENT sid="483" pm="."><plain>Animals were observed weekly for tumor development for 5 to 8 weeks. </plain></SENT>
<SENT sid="484" pm="."><plain>The final tumor weights at the time of animal sacrifice were recorded. </plain></SENT>
<SENT sid="485" pm="."><plain>The size and weights of the tumor masses were similar in CTHRC1 overexpressing and control groups. </plain></SENT>
</text></p><p><text><SENT sid="486" pm="."><plain>(TIF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0070324.s002.tif"><caption><p><text><SENT sid="487" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0070324.s003"><label>Figure S3</label><caption><p><text><SENT sid="488" pm="."><plain>CTHRC1 is required for HA22T cell invasion through 3D collagen matrix. </plain></SENT>
</text></p><p><text><SENT sid="489" pm="."><plain>(TIF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0070324.s003.tif"><caption><p><text><SENT sid="490" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="491" pm="."><plain>RNAi reagents were obtained from the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica. </plain></SENT>
<SENT sid="492" pm="."><plain>We also thank the Second Core Laboratory of National Taiwan University Hospital for technical support. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0070324-ElSerag1"><text><SENT sid="493" pm="."><plain>1 El-SeragHB, RudolphKL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557–7256.17570226 </plain></SENT>
</text></ref><ref id="pone.0070324-Yu1"><text><SENT sid="494" pm="."><plain>2 YuMC, YuanJM, GovindarajanS, RossRK (2004) Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 14: 703–709. </plain></SENT>
</text></ref><ref id="pone.0070324-Schafer1"><text><SENT sid="495" pm="."><plain>3 SchaferDF, SorrelMF (1999) Hepatocellular carcinoma. Lancet 353: 1253–1257.10217098 </plain></SENT>
</text></ref><ref id="pone.0070324-Hsu1"><text><SENT sid="496" pm="."><plain>4 HsuHC, JengYM, MaoTL, ChuJS, LaiPL, et al (2000) β-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 157: 763–770.10980116 </plain></SENT>
</text></ref><ref id="pone.0070324-Hsu2"><text><SENT sid="497" pm="."><plain>5 HsuHC, HuangAM, LaiPL, ChienWM, PengSY, et al (1994) Genetic alterations at the splice junction of p53 gene in human hepatocellular carcinoma. Hepatology 19: 122–128.7903951 </plain></SENT>
</text></ref><ref id="pone.0070324-Pyagay1"><text><SENT sid="498" pm="."><plain>6 PyagayP, HeroultM, WangQ, LehnertW, BeldenJ, et al (2005) Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 96: 261–268.15618538 </plain></SENT>
</text></ref><ref id="pone.0070324-LeClair1"><text><SENT sid="499" pm="."><plain>7 LeClairRJ, DurmusT, WangQ, PyagayP, TerzicA, et al (2007) Cthrc1 is a novel inhibitor of transforming growth factor-beta signaling and neointimal lesion formation. Circ Res 100: 826–833.17322174 </plain></SENT>
</text></ref><ref id="pone.0070324-Yamamoto1"><text><SENT sid="500" pm="."><plain>8 YamamotoS, NishimuraO, MisakiK, NishitaM, MinamiY, et al (2008) Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell 15: 23–36.18606138 </plain></SENT>
</text></ref><ref id="pone.0070324-Tang1"><text><SENT sid="501" pm="."><plain>9 TangL, DaiDL, SuM, MartinkaM, LiG, et al (2006) Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res 12: 3716–3722.16778098 </plain></SENT>
</text></ref><ref id="pone.0070324-Edmonson1"><text><SENT sid="502" pm="."><plain>10 EdmonsonHA, SteinerPE (1954) Primary carcinoma of the liver: A study of 100 among 489,000 necropsies. Cancer (Phila.) 7: 462–503.13160935 </plain></SENT>
</text></ref><ref id="pone.0070324-Edge1"><text><SENT sid="503" pm="."><plain>11Edge SB (2010) AJCC cancer staging manual (7th ed). </plain></SENT>
<SENT sid="504" pm="."><plain>New York, NY: Springer. </plain></SENT>
</text></ref><ref id="pone.0070324-Wang1"><text><SENT sid="505" pm="."><plain>12 WangYC, ChenYL, YuanRH, PanHW, YangWC, et al (2010) Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. Carcinogenesis 31: 1516–1522.20525879 </plain></SENT>
</text></ref><ref id="pone.0070324-Wessel1"><text><SENT sid="506" pm="."><plain>13 WesselD, FuggeUI (1984) A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Analytical Biochemistry 138: 141–143.6731838 </plain></SENT>
</text></ref><ref id="pone.0070324-Sahai1"><text><SENT sid="507" pm="."><plain>14 SahaiE, MarshallCJ (2002) RHO-GTPases and cancer. Nat Rev Cancer 2: 133–134.12635176 </plain></SENT>
</text></ref><ref id="pone.0070324-Wong1"><text><SENT sid="508" pm="."><plain>15 WongCC, WongCM, AuSL, NgIO (2010) RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N’Rho move it. Liver Int 30: 642–656.20726051 </plain></SENT>
</text></ref><ref id="pone.0070324-Ishizaki1"><text><SENT sid="509" pm="."><plain>16 IshizakiT, MaekawaM, FujisawaK, OkawaK, IwamatsuA, et al (1996) The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 15: 1885–1893.8617235 </plain></SENT>
</text></ref><ref id="pone.0070324-Janssen1"><text><SENT sid="510" pm="."><plain>17 JanssenME, KimE, LiuH, FujimotoLM, BobkovA, et al (2006) Three-dimensional structure of vinculin bound to actin filaments. Mol Cell 21: 271–281.16427016 </plain></SENT>
</text></ref><ref id="pone.0070324-Owen1"><text><SENT sid="511" pm="."><plain>18 OwenJD, RuestPJ, FryDW, HanksSK (1999) Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol Cell Biol 19: 4806–4818.10373530 </plain></SENT>
</text></ref><ref id="pone.0070324-Burridge1"><text><SENT sid="512" pm="."><plain>19 BurridgeK, TurnerCE, RomerLH (1992) Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J Cell Biol 119: 893–903.1385444 </plain></SENT>
</text></ref><ref id="pone.0070324-Zutter1"><text><SENT sid="513" pm="."><plain>20 ZutterMM, SunH, SantoroSA (1998) Altered integrin expression and the malignant phenotype: the contribution of multiple integrated integrin receptors. </plain></SENT>
<SENT sid="514" pm="."><plain>J. </plain></SENT>
<SENT sid="515" pm="."><plain>Mammary Gland Biol. Neoplasia 3: 191–200. </plain></SENT>
</text></ref><ref id="pone.0070324-Jeng1"><text><SENT sid="516" pm="."><plain>21 JengYM, ChangCC, HuFC, ChouHY, KaoHL, et al (2008) RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 48: 1118–1127.18802962 </plain></SENT>
</text></ref><ref id="pone.0070324-Dale1"><text><SENT sid="517" pm="."><plain>22 DaleRM, SissonBE, TopczewskiJ (2009) The emerging role of Wnt/PCP signaling in organ formation. Zebrafish 6: 9–14.19250029 </plain></SENT>
</text></ref><ref id="pone.0070324-Chung1"><text><SENT sid="518" pm="."><plain>23 ChungS, KimS, YoonJ, AdlerPN, YimJ (2007) The balance between the novel protein target of wingless and the Drosophila Rho-associated kinase pathway regulates planar cell polarity in the Drosophila wing. Genetics 176: 891–903.17409077 </plain></SENT>
</text></ref><ref id="pone.0070324-Hotchin1"><text><SENT sid="519" pm="."><plain>24 HotchinNA, HallA (1995) The assembly of integrin adhesion complexes requires both extracellular matrix and intracellular rho/rac GTPases. J Cell Biol 131: 1857–1865.8557752 </plain></SENT>
</text></ref><ref id="pone.0070324-Ridley1"><text><SENT sid="520" pm="."><plain>25 RidleyAJ, HallA (1992) The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70: 389–399.1643657 </plain></SENT>
</text></ref><ref id="pone.0070324-Park1"><text><SENT sid="521" pm="."><plain>26 ParkEH, KimS, JoJY, KimSJ, HwangY, et al (2013) Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. Carcinogenesis 2013 34: 694–702. </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
